Pharma and diagnostics companies need to strengthen alignment in Alzheimer’s disease research-to help turn science and data into actionable medical innovations.
Edward I. Ginns, MD, PhD
Advertisement
Articles by Edward I. Ginns, MD, PhD
Advertisement
Latest Updated Articles
Closer Pharma-Diagnostic Collaboration is Key to Alzheimer’s Drug R&DPublished: November 1st 2018 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
How IQVIA and Veeva Are Improving Efficiency and Data Management in Clinical Trials
2
Operational Challenges of Using Overall Survival as a Primary Endpoint
3
ACT Brief Weekly Recap: Partnerships, Site Networks, and AI Reshaping Clinical Trials
4
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
